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Abstract
Background: Estimated medical costs (“T”) and QALYs (“Q”) associated with smoking are frequently used in cost-
utility analyses of tobacco control interventions. The goal of this study was to understand how researchers have
addressed the methodological challenges involved in estimating these parameters.
Methods: Data were collected as part of a systematic review of tobacco modeling studies. We searched five
electronic databases on July 1, 2013 with no date restrictions and synthesized studies qualitatively. Studies were
eligible for the current analysis if they were U.S.-based, provided an estimate for Q, and used a societal perspective
and lifetime analytic horizon to estimate T. We identified common methods and frequently cited sources used to
obtain these estimates.
Results: Across all 18 studies included in this review, 50 % cited a 1992 source to estimate the medical costs
associated with smoking and 56 % cited a 1996 study to derive the estimate for QALYs saved by quitting or
preventing smoking. Approaches for estimating T varied dramatically among the studies included in this review.
T was valued as a positive number, negative number and $0; five studies did not include estimates for T in their
analyses. The most commonly cited source for Q based its estimate on the Health Utilities Index (HUI). Several
papers also cited sources that based their estimates for Q on the Quality of Well-Being Scale and the EuroQol five
dimensions questionnaire (EQ-5D).
Conclusions: Current estimates of the lifetime medical care costs and the QALYs associated with smoking are
dated and do not reflect the latest evidence on the health effects of smoking, nor the current costs and benefits
of smoking cessation and prevention. Given these limitations, we recommend that researchers conducting
economic evaluations of tobacco control interventions perform extensive sensitivity analyses around these
parameter estimates.
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Background
Decision-makers, faced with limited financial resources,
must typically consider the cost and cost-effectiveness of
different options when deciding which policies and
programs to implement [1]. As recommended by the
Panel on Cost-Effectiveness in Health and Medicine for
economic evaluations [1–3], cost-utility analyses typic-
ally express outcomes in terms of cost per quality-
adjusted life year (QALY), a standard measure that
allows decision-makers to make comparisons across
different types of interventions.
Modeling the potential impacts of policies on
population-level health is of particular interest to the
field of tobacco control given the current regulatory en-
vironment in the United States (U.S.). The Food and
Drug Administration (FDA) is required to evaluate the
economic impact of proposed regulatory options [4] and
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has expressed interest in employing mathematical mod-
eling methods to assess the effects of potential policies
[5, 6]. The lifetime medical costs associated with smok-
ing (“T”) and the number of quality-adjusted life years
associated with smoking prevention or cessation (“Q”)
are essential drivers of the cost-effectiveness of a policy
option, but methodologically challenging to estimate for
two reasons: first, the true values of these parameters
can change with evolving evidence on the harms of
smoking [7–9] and rising medical costs; and second, the
costs and benefits of smoking prevention and cessation
are distal and do not accrue until years following an
intervention.
The current study builds upon existing reviews of eco-
nomic evaluations in tobacco control [8, 10]. While
these previous reviews focused on synthesizing the find-
ings of economic evaluations [8, 10] and on standardiz-
ing cost-effectiveness ratios to facilitate comparisons
between interventions [8], they do not provide in-depth
assessments of the models used to generate findings for
individual studies. The aim of the current study is to ad-
dress this gap by providing a detailed investigation into
how the parameters T and Q have been estimated in
tobacco control literature.
Methods
Data for this study were collected as part of a systematic
review of studies that employed mathematical modeling
methods to project tobacco-related outcomes [11]. The
methods and overarching descriptive findings from that
review can be found elsewhere [11, 12], and PRISMA
guidelines have been adhered to. Briefly, we searched
five electronic databases (CINAHL, Embase, Psy-
chINFO, PubMed, and EconLit) on July 1, 2013 with
no date restrictions and synthesized studies qualitatively
(Additional file 1: Table S1). Only peer-reviewed, pub-
lished literature in English language was eligible for inclu-
sion. Models that project only retrospectively (i.e., analyze
the historical burden of disease) were excluded from this
review. Studies that model individual smoker trajectories
that do not also project population-level outcomes were
also excluded. Animal studies, human genetics studies,
and posters and abstracts without full text records were
not included this review.
Eligible studies and search strategy
In the current analysis, studies were eligible if they esti-
mated an economic outcome [11]; were conducted in
the U.S.; provided an estimate for Q; and used a societal
perspective and lifetime analytic horizon to estimate T.
We included only U.S.-based studies because the U.S.
healthcare system differs from those of most other in-
dustrialized countries and, thus, costs spent to treat a
disease in the U.S. are not necessarily comparable to
those spent on the same condition elsewhere. We in-
cluded only studies that used a societal perspective and
lifetime analytic horizon to estimate T because studies
without these specifications could reasonably exclude T
from their analyses; we wanted to capture all studies that
were structured in such a way that, from a methodo-
logical perspective, should have provided an estimate for
T. Two pairs of coders independently reviewed the title
and abstract of each included record, then two coders
reviewed the full texts of articles that met the inclusion
criteria and exhibited moderate agreement (k = 0.53)
during this phase of the review process.
Data extraction
Three authors conducted data extraction for each study
in pairs (SF, AG, LT). We employed a data extraction
form with open-ended questions to capture the hetero-
geneous ways in which authors describe their methods
for calculating Q and T. The form included items about
the target population for which Q was estimated,
methods for estimating T and Q (including cited
sources), discounting practices, and discussion around
decisions not to estimate T.
Analysis
Given the goals of this review and the heterogeneity of
the included studies, we synthesized studies qualitatively.
We performed our analysis in two stages. First, we iden-
tified the methods used to estimate Q and T in each in-
cluded study. Second, we identified sources that were
cited for estimating these parameters and investigated
these primary sources. While we did not conduct a for-
mal risk of bias assessment for the studies included in
this review, we evaluated the quality and relevance of
these frequently cited sources, based on criteria devel-
oped to address this review’s questions, to better under-
stand how researchers are estimating Q and T.
We developed tables to describe the methods used to
estimate both parameters. We included information
about whether the authors discounted these parameters
at 3 %, which is standard practice [3]. We also docu-
mented whether each study assessed uncertainty with re-
gard to estimating these parameters. We tagged studies
as having explored uncertainty for these parameter esti-
mates if they either ran their analysis with multiple
discount rates for the same base value or employed mul-
tiple base values.
To visualize the network of citations used to estimate
T and Q and illustrate the chronological link between
studies, we conducted a bibliometric analysis using
HistCite Version 2009.08.24. We examined the studies
included in this review and the studies they cited as
sources for estimating T and Q. The analysis was limited
to studies indexed in Web of Science.
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Results and discussion
Fifty-seven studies from our overarching systematic re-
view estimated economic outcomes [11] and were con-
ducted in the U.S. Of those, 26 studies estimated QALYs
as an outcome [13–38]. Eighteen of those studies
employed a societal perspective and lifetime analytic
horizon to estimate T and, thus, were included in our re-
view. Years of publication ranged from 1997 to 2012.
The majority of studies targeted the general population,
and evaluated smoking cessation programs or policies.
The study selection process is illustrated in Fig. 1.
Medical costs attributable to smoking (T)
Information on estimates of T can be found in
Table 1. Five studies did not estimate T in their ana-
lyses [18, 23, 24, 26, 36]. Of the 13 studies that pro-
vided estimates for T, 11 studies (85 %) discounted T
by 3 % [13, 14, 21, 25, 27, 29, 31, 34, 35, 37, 38].
Nine studies (69 %) accounted for uncertainty in their
estimate by using different assumptions for the value
of T [21, 25, 27, 29, 31, 34, 35, 37, 38].
Summary of medical costs attributable to smoking (T)
Hodgson
Seven papers (54 %) directly cited a 1992 paper by Hodgson
[39] as a source for estimating T [13–16, 35, 37, 38]. A
study conducted by Holtgrave et al. [21] cited Wang et al.
[38] as a source for estimating T. Wang et al., in turn, cited
Hodgson’s paper. Thus, Holtgrave et al. indirectly cited
Hodgson for this estimate. A study by Ruger et al. [31] also
seems to indirectly cite Hodgson. Ruger et al. cited three
studies [18, 20, 40] as sources for their upper value estimate
for T. Only one of these studies, conducted by Cromwell
et al. [18], appears to include a discussion of the value used
by Ruger et al. Cromwell et al.’s study did not include a pri-
mary calculation for this value; it cited a publication by
Gold et al. [41] We could not find this value in the publica-
tion by Gold et al.; this value appears to be the estimate of
the excess lifetime medical expenditures incurred by
smokers presented in Hodgson’s paper.
Four of the seven (57 %) studies that directly cited
Hodgson’s estimate did so only to estimate T for adults;
they employed other methods to estimate T for youth
[13–16]. In these four studies, no sensitivity analysis was
conducted around the value of T for adults. Villanti
et al. and Wang et al. [37, 38] used Hodgson’s estimate
as the highest value in a sensitivity analysis, while
Holtgrave et al. [21] used Hodgson’s estimate as the
base-case estimate.
Hodgson estimated the medical expenditures associ-
ated with smoking based on gender, age, smoking inten-
sity and survival status. He considered ages from
17 years until death (17–34, 35–44, 45–54, 55–64, 65–
74, 75–84, 85+) and four levels of smoking intensity.
The analysis incorporated expenditures from Medicare,
Medicaid, direct costs and other private costs (primarily
from private insurance). Hodgson based his estimates on
data from the National Health Interview Survey (NHIS)
(hospital and physician services); National Nursing
Home Survey and National Health and Nutrition Exam-
ination Survey Epidemiologic Follow-up Study (nursing-
home expenditures); American Cancer Society’s Cancer
Prevention Study II (mortality); and National Medical
Care Utilization and Expenditure Survey and Medicare
data files (medical care charges). Hodgson does not spe-
cify the years during which these surveys were fielded.
He employed a 3 % discount rate. Additional analyses
were conducted with a 5 % discount rate.
Medical Expenditure Panel Survey
Four of the seven (57 %) studies citing Hodgson also
cited the Medical Expenditure Panel Survey (MEPS) [42]
as a source for estimating T [13–16]. These studies used
MEPS data to estimate T for youth and Hodgson’s data
to estimate T for adults. The MEPS is composed of two
major components; one collects data from individual
households and their medical providers, and one collects
data on employer-based health insurance. The MEPS
also surveys healthcare organizations and facilities
identified by respondents [42]. None of the authors
who cited the MEPS as a source for estimating T spe-
cifically described which MEPS data they used for
their analyses. No sensitivity analyses were conducted
around this value.
Warner et al.
Two studies [37, 43] (15 %) employed an estimate gener-
ated by Warner et al. [43] for their lowest value in a sen-
sitivity analysis for T. To obtain this estimate, Warner
et al. used data from existing literature and managed
care organizations (MCOs) to inform a computer simu-
lation model that tracks members of a hypothetical
Studies included in overarching 
systematic review
(n=263)
206 studies excluded; did not 
estimate an economic outcome 
and/or was not U.S.-based
Studies with economic evaluations in 
the U.S.
(n=57)
31 studies excluded; did not 
estimate QALYs as an outcome
Studies assess QALY as an outcome
(n=26)
8 studies excluded; did not use 
societal perspective and/or 
lifetime analytic horizon to 
estimate T
Studies included in synthesis
(n=18)
Fig. 1 Flowchart of included studies
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Table 1 Methods for estimating medical costs attributable to smoking (T)
First author, year published Source for lifetime medical costs attributable to smoking Discounted at 3 % Assessment of uncertainty
Ahmad, 2005 [13] Hodgson, 1992 [39] Yes No
aMedical Expenditure Panel Survey [66]
Ahmad, 2005 [14] Hodgson, 1992 [39] Yes No
aMedical Expenditure Panel Survey [66]
Ahmad, 2005 [15] Hodgson, 1992 [39] No No
Medical Expenditure Panel Survey [66]
Ahmad, 2008 [16] Hodgson, 1992 [39] Not stated No
aMedical Expenditure Panel Survey [66]
Cromwell, 1997 [18] Did not include lifetime medical costs associated
with smoking; included discussion
N/A N/A
Holtgrave, 2009 [21] Wang, 2001 [38] Yes Yes
Sloan, 2004 [45]
Warner, 2004 [43]
Javitz, 2004 [23] Did not include lifetime medical costs associated
with smoking; included discussion
N/A N/A
Javitz, 2011 [24] Did not include lifetime medical costs associated
with smoking; included discussion
N/A N/A
Kahn, 2008 [25] Kaiser Permanente Southern California (no citation given) Yes Yes
The Diabetes Prevention Program Research Group [67]
Keeler, 2002 [26] Did not include lifetime medical costs associated
smoking; did not include discussion
N/A N/A





McMahon, 2011 [29] Cipriano, 2010 [73] Yes Yes
SEER-Medicare linked data (no citation given)





Solberg, 2006 [34] Musich, 2003 [75] Yes Yes
Keehan, 2004 [76]
Hoffman, 2001 [77]
Tengs, 2001 [35] Hodgson, 1992 [39] Yes Yes
Tran, 2002 [36] Did not include lifetime medical costs associated
smoking; did not include discussion
N/A N/A
Villanti, 2012 [37] Hodgson, 1992 [39] Yes Yes
Warner, 2004 [43]
Cromwell, 1997 [18]
Wang, 2001 [38] Hodgson, 1992 [39] Yes Yes
Manning, 1989 [44]
aNo citation was given; “Medical Expenditure Panel Survey” was only referenced in the text
bStates that medical costs were discounted but does not specify at 3 %. We assume a 3 % discount rate was used because the paper appears to reference the
U.S. Panel on Cost-Effectiveness in Health and Medicine guidelines for performing the analysis
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MCO. Warner et al. value T negatively; the estimate as-
sumes that former smokers incur greater medical costs
compared to continuing smokers as a result of a longer
lifespan. The authors discounted costs at 3 %.
Manning et al.
Wang et al. [38] used an estimate by Manning et al. [44]
as their lowest estimate for T. Holtgrave et al. [21], who
indirectly cited Manning et al. (via Wang et al.) for this
estimate, used this value in their base-case analysis. The
sources of this estimate were the RAND National Health
Insurance Experiment and the NHIS. In calculating the
differential medical care costs for smokers versus never
smokers, Manning et al. controlled for risky behaviors
such as alcohol use. Thus, Manning et al.’s estimate of T
is lower than Hodgson’s.
Sloan et al.
Holtgrave et al. used Sloan et al.’s [45] estimate to calcu-
late their highest estimate of T in a sensitivity analysis.
Sloan et al. estimated the annual private medical care
cost of smoking for a 24 year-old. Holtgrave et al. calcu-
lated lifetime medical costs by assuming that this cost
would be incurred annually over many years; they dis-
counted their estimate at 3 % over 27 years.
Other methods
Four studies [25, 27, 29, 34] (31 %) estimated T by using
other sources that directly tracked medical costs in-
curred and/or by consulting literature on the costs of
treating specific tobacco-related diseases. These sources
can be found in Table 1. Two of these studies did not
provide details about their sources, such as values of the
inputs in their models [25, 27].
Studies that omitted T
Five studies (38 %) excluded estimates of T from their
analyses [18, 23, 24, 26, 36]. Two of these studies did
not explicitly note this omission [26, 36]. One source
acknowledged the omission without discussion [24].
Two studies [18, 23] cited difficulty determining
whether smoking cessation produces long-term in-
creased or decreased healthcare costs in discussing
their omission of T.
Studies that valued T at $0
Two studies (15 %) included an estimate of $0 for T as
their base-case estimates [31, 37]. In discussing their ra-
tionale for valuing T at $0, the authors of these studies
cited previously published studies [18, 20, 23, 41].
Synthesis
Hodgson’s estimate, published in 1992, was the most fre-
quently cited source; nine papers cited this study. This
estimate, however, was only one of several used across
the studies in this review. Estimates of T assumed posi-
tive, negative, and $0 values, illustrating the heterogen-
eity of assumptions used across studies.
QALYs associated with preventing or quitting smoking (Q)
Information on estimates of Q can be found in Table 2.
Most studies estimated Q for adult populations. Two
studies focused on youth [21, 38] and five focused on
populations that included youth and adults [13–16, 35].
All but two [15, 16] papers discounted QALYs at 3 %.
The authors of 10 [18, 21, 23–26, 31, 35–37] of the 18
studies in this review accounted for uncertainty by run-
ning their analyses with different values for Q. We iden-
tified three preference-based health-state classification
systems and one additional method that were used to
calculate values and utilities for Q.
Health Utilities Index
A paper by Fiscella et al. [20] was the most frequently
cited source for obtaining utility values to estimate Q.
Seven [18, 23, 24, 26, 27, 31, 36] of the 18 studies (39 %)
in this analysis directly cited this paper. Estimates from
three additional studies – conducted by Wang et al. [38]
Villanti et al. [37] and Holtgrave et al. [21] – were indir-
ectly based on those published by Fiscella et al. [20]
Wang et al. [38] cited a paper by Cromwell et al. [18] as
their source for estimating Q; Cromwell et al. [18], in
turn, based their estimate on the paper by Fiscella et al.
[20] Villanti et al. [37] and Holtgrave et al. [21] cited
Wang et al. [38] as a source for estimating Q. Villanti
et al. [37] also obtained QALY weight estimates from
Javitz et al. [23], who based their estimates on those of
Fiscella et al. [20].
Fiscella et al. developed age- and gender-specific
QALY estimates for smokers and former smokers (age
groups: 25–29, 30–34, 35–39, 40–44, 45–49, 50–54, 55–
59, 60–64, 65–69). They based their estimates on years
of healthy life measures, developed with 1991 NHIS
data. Two domains were measured in the NHIS to assess
health status: perceived health and role limitation [46].
Fiscella et al. linked the NHIS data to the HUI. The HUI
refers to a family of systems that can be used to produce
health-related quality of life utility scores [47, 48].
Fiscella et al. noted that the NHIS does not directly
ask the questions needed to estimate QALYs from the
HUI, but they stated that their estimates were reason-
ably valid.
Quality Of Well-being Scale
Six studies [13–16, 21, 35] (33 %) based their estimates
for Q on the Quality of Well-Being (QWB) Scale [49]. In
four of these studies, the authors cited only personal
communication with RM Kaplan as the source for the
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estimates [13–15, 35]. For our analysis, we assume that
these four studies employed the methodology for esti-
mating utility values for Q described in a 2007 paper by
Kaplan et al. [49].
Kaplan et al. estimated age- and gender-specific QALY
estimates for individuals aged 18–70. These estimates
accounted for smoking intensity. To assess health, the
QWB Scale produces preference weights based on 1)
symptoms and problems and 2) dysfunction (mobility,
physical activity, social activity). Data for the QWB Scale
were obtained from pooled 1987, 1990 and 1994 NHIS
data. Kaplan et al. noted that the NHIS does not directly
ask the questions needed to input data for the QWB
Scale, but the authors believe that their method pro-
duces good estimates.
EQ-5D index
Two studies [25, 29] (11 %) based their QALY estimates
on EQ-5D index scores [50, 51]. The EQ-5D provides
age- and gender- specific health-related quality of life
scores associated with specific medical conditions. To
assess quality of life, the EQ-5D measures mobility, self-
Table 2 Methods for estimating QALYS associated with quitting or preventing smoking (Q)
First author, year
published
Target population Source for QALY weights Method of
determining QALYSc
Discounted at 3 % Assessment of
uncertainty
Ahmad, 2005 [13] Entire California population aKaplan, 2007 [49] QWB Scale Yes No
Ahmad, 2005 [14] Entire U.S. population aKaplan, 2007 [49] QWB Scale Yes No
Ahmad, 2005 [15] Entire California population aKaplan, 2007 [49] QWB Scale, Other No No
Erikson, 1995 [46]
Ahmad, 2008 [16] Entire U.S. population aKaplan, 2007 [49] QWB Scale, Other Not stated No
Erikson, 1995 [46]
Cromwell, 1997 [18] Adults in the U.S. Fiscella, 1996 [20] HUI Yes Yes
Holtgrave, 2009 [21] Youth in the U.S. Kaplan, 2007 [49] HUI, QWB Scale Yes Yes
Wang, 2001 [38]
Javitz, 2004 [23] Adults in the U.S. Fiscella, 1996 [20] HUI, Other Yes Yes
Erickson, 1995 [46]
Javitz, 2011 [24] Adults in the U.S. Fiscella, 1996 [20] HUI, Other Yes Yes
Erickson, 1995 [46]
Kahn, 2008 [25] Adults in the U.S. Sullivan, 2006 [50] EQ-5D Index Yes Yes
Keeler, 2002 [26] Adults in the U.S. Fiscella, 1996 [20] HUI Yes Yes
Knight, 2010 [27] Adults in the U.S. bFiscella, 1996b HUI Yes bNot clear
McMahon, 2011 [29] Adults in the U.S. Hanmer, 2006 [51] EQ-5D Index Yes No
Ruger, 2008 [31] Low-income pregnant
women in the U.S.
Fiscella, 1996 [20] HUI, Other Yes Yes
Cromwell, 1997 [18]
Erickson, 1997 [46]




Tengs, 2001 [35] Entire U.S. population aKaplan, 2007 [49] QWB Scale, Other Yes Yes
Erikson, 1995 [46]
Tran, 2002 [36] Adults in the U.S. Fiscella, 1996 [20] HUI Yes Yes
Villanti, 2012 [37] Adult in the U.S. Wang, 2001 [38] HUI Yes Yes
Javitz, 2004 [23]
Wang, 2001 [38] Students in the U.S. Cromwell, 1997 [18] HUI Yes No
aCited as “R. M. Kaplan, 1999, personal communication” in text. For the purpose of this analysis, we assume that the methodology described in [49] was used in
this paper
b“Utility values for the various model states were also drawn from a variety of literature sources [20–27].” Fiscella was one of these sources. We assume it is for
QALYs associated with quitting smoking. Notes that sensitivity analyses were conducted for utility values, but not clear if sensitivity analysis done specifically for
utility values associated with quitting smoking
cHUI Health Utilities Index, QWB quality of well-being scale, EQ-5D EuroQol five dimensions questionnaire
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care, typical activities, pain/discomfort and anxiety/de-
pression [50]. Kahn et al. [25] cited a source that
used the EQ-5D index scores based on data from the
2000–2002 MEPS [50]. McMahon et al. [29] cited a
source that obtained EQ-5D index scores from the
2001 MEPS [51].
Other calculations
Six papers [15, 16, 23, 24, 31, 35] (33 %) cited a study by
Erickson et al. [46] as the source for obtaining QALY es-
timates associated with smoking. Two of these papers at-
tributed authorship of this article to the Centers for
Disease Control and Prevention instead of to Erickson
et al. [24, 31]. In three studies, Erickson et al.’s data was
used to calculate QALYs for youth [15, 16, 35].
Erickson et al. did not specifically present data related
to smoking status. Instead, they calculated average
health-related quality of life by age (age groups: 0–5, 5–
10, 10–15, 15–20, 20–25, 25–30, 30–35, 35–40, 40–45,
45–50, 50–55, 55–60, 65–70, 75–80, 85+) based on
1990 NHIS data. To obtain the values for the QALYs as-
sociated with smoking from this data, researchers ex-
trapolated based on other sources of information.
Solberg et al. [34] employed another method whereby
they identified QALY weights associated with chronic
and acute conditions, and then applied those weights to
specific conditions associated with smoking. The authors
calculated the weight for stroke separately from other
conditions.
Synthesis
All of the approaches described are based on surveys of
the general population. Two approaches [20, 49] based
their QALY estimates on NHIS data that were collected
nearly 25 years ago. These studies note that the NHIS
does not directly ask the questions needed to estimate
QALYs based on the index/scale being used, but that the
authors believe their estimates to be valid [20, 49]. The
QWB Scale was the only approach to explicitly account
for smoking intensity [49]. Erickson et al. was the only
source of data used to estimate QALYs for youth [46].
Visualization of results
The chronological connections between the 18 studies
in this review and the studies cited as sources for T and
Q can be seen in Fig. 2. Forty-one studies were indexed
in Web of Science and are presented in this figure. The
largest nodes in this figure represent the publications
that were cited most frequently by the studies included
in the collection; these values do not represent the num-
ber of times a publication is cited in the general litera-
ture. The two largest nodes (“40” and “21”) represent the
studies published by Hodgson [39] and Fiscella et al.
[20]. The top six most frequently cited studies were pub-
lished in the 1990’s.
Conclusions
The current study systematically evaluated how re-
searchers have estimated T and Q in economic evalua-
tions of tobacco control interventions. The most
frequently cited papers for these estimates were pub-
lished in 1992 (Hodgson) and 1996 (Fiscella et al.), re-
spectively. These estimates do not take into account the
technological advances in the treatment of smoking-
related diseases in the past 20 years [52] or up-to-date
research about the effects of smoking [9, 53, 54]. Not-
ably, the 2014 Surgeon General’s report concluded that
smoking causes more diseases than previously thought
[7]. Changes in assumptions about the effects of smok-
ing and the course of illness for individuals with
smoking-related diseases may drastically change esti-
mates of T and Q. As a comparison, researchers have
published updated estimates of the lifetime medical costs
associated with HIV infection as care and treatment for
HIV/AIDS has developed, and each update has produced
new findings [55, 56].
We noted substantial heterogeneity with regard to the
way in which T was valued in the literature. This hetero-
geneity is problematic because it is difficult to compare
studies that employ different methods. Developing a
standard approach for estimating T would make it easier
to include the true costs of smoking cessation and pre-
vention in comparisons and syntheses of economic eval-
uations of tobacco control interventions, thus improving
the evidence base upon which decisions could be made.
Of the approaches to estimating T, perhaps the most
controversial is the assignment of a negative value to the
parameter. We argue that treating T in this way is prob-
lematic. From a methodological standpoint, estimating T
negatively may mean that the researcher has not consid-
ered the costs and benefits of smoking cessation equally.
A negative value assumes that former smokers incur
more medical costs than continuing smokers due to a
longer lifespan. While this may be true, it is possible that
lifetime earnings resulting from a longer lifespan
could outweigh the excess medical costs [57]. From
an ethical standpoint, valuing T negatively biases the
analysis against an outcome – smoking cessation –
that society has deemed to be desirable. Biasing the
analysis in this way is inconsistent with a population
health approach [58].
Accurately estimating the costs and benefits associated
with preventing or quitting smoking has important ap-
plications. In 2014, the FDA published a Regulatory Im-
pact Analysis (RIA) to assess the economic impact of a
proposed rule [4]. In their analysis, the FDA considered
the cost of the proposed regulation to smokers and
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estimated that the “lost consumer surplus” amounted to
a 70 % reduction in the welfare gain experienced by indi-
viduals who would quit smoking as a result of the regu-
lation. Prominent economists [59] and others [60] argue
that this estimate overvalues the cost and undervalues
the benefit of smoking cessation. The development of
standard, up-to-date estimates of the costs and benefits
associated with smoking cessation and prevention could
help avoid the use of estimates in future RIAs that bias
the results against the public health goal of saving lives
through smoking cessation and prevention. Given the
limitations associated with current estimates of T and Q,
we recommend that researchers conducting economic
evaluations of tobacco control interventions perform
extensive sensitivity analyses, including threshold ana-
lyses, around these parameter estimates.
We identified additional gaps in the existing literature
and suggest directions for future research. First, the most
commonly used instruments to classify health states (the
HUI, QWB Scale and EQ-5D) employ different methods
[61–63], and comparisons of these tools have found that
they produce different findings about the health status as-
sociated with certain conditions [62, 64]. Future analyses
might assess differences in how these instruments esti-
mate the quality of life associated with smoking. Second,
authors employing the HUI and QWB Scale to estimate Q
noted that the surveys they used estimate health state
preferences did not directly ask the questions needed to
dehsilbupraeY
Fig. 2 Bibliometric analysis examining the studies included in this review and the papers they cited as sources for estimating T and Q. Numbers
next to nodes correspond to citation numbers in the Reference section
Feirman et al. BMC Public Health  (2016) 16:646 Page 8 of 11
populate their instruments. Researchers might consider
developing a survey that would address this limitation, in
addition to exploring other methods to estimate Q. It is
unclear whether there is a gold standard method for esti-
mating Q; our findings suggest that the field would benefit
from research that investigates and refines such methods.
Last, the studies in this review that evaluated prevention-
focused interventions [21, 38] employed estimates devel-
oped for smoking cessation. To our knowledge, no true
estimates for the costs and benefits associated with smok-
ing prevention have been published, even in newer studies
examining the impact of smoking prevention [65].
This study considers how T and Q were estimated,
and it focuses on U.S. studies. An analysis of how other
measures – such as productivity over the lifetime and
life-years saved – have been modeled in economic evalu-
ations, and an analysis of international studies, may pro-
vide further insight into the current state of economic
evaluation research.
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